No. | Abbreviation | Pivotal study | Effect at LOAEL | Point of departure (mg/kg day) | Factor elimination t1/2 human/animal | Assessment factors 1. Duration 2. Inter-dyn. 3. Intra | Human equivalent dose (μg/kg day) | Concentration in DW (µg/L) | GFS (μg/L) |
---|---|---|---|---|---|---|---|---|---|
1 | PFBA | Hepatocellular hypertrophy; thyroid hyperplasia/hypertrophy | 6 | 8 | 10 2.5–1 10 –––– 250–100 | 3–7.5 | 10–52a | 10 | |
3 | PFHxA | Lower urine pH, kidney histology | 15 | 327 | – 2.5 10 –––– 25 | 1.84 | 6.42 | 6 | |
5 | PFOA | Human [94] supported by 26 weeks oral, monkey ♂ [95]; 17 days oral mouse ♀ [53] | Reduced protection against A/H3N2-virus provided by influenza vaccination [94]. Supported by elevated liver weight [95]; delayed mammary gland development [53] | Serum concentration at steady state: 90 µg/L human serum, converted to human equivalent dose | 0.02037 | 0.071 | 0.1c | ||
6 | PFNA | Microscopic liver lesions; hepatocellular hypertrophy | 0.025 | 50 | 3* – – – 10** –––– 30 | 0.0167 | 0.0583 | 0.06 | |
8 | PFBS | 90 days oral, rat ♂ [98] | Reduced erythrocytes, hemoglobin and hematocrit | 60 | 146 | 10 2.5 10 –––– 250 | 1.64 | 5.74 | 6 |
9 | PFHxS | 42 days oral, rat ♂ [99] | Raised liver weight, hepatocellular hypertrophy; thyroid hyperplasia; reduced hematocrit | 1 | 90 | 15 2.5 10 –––– 375 | 0.03 | 0.1037 | 0.1b |
11 | PFOS | 2 years oral rat ♂ [100]; 26 weeks oral monkey ♂ [3, 101]; 420 days oral monkey [102]; 28 days oral mouse ♂ [103,104,105,106] | Hepatocellular hypertrophy [100]; low cholesterol [3, 101]; low cholesterol [102]; increased NK activity, inhibited IgM production [103,104,105,106] | Serum concentration at steady state: 20 µg/L human serum as middle from the pivotal studies [17, 38], converted to human equivalent dose | 0.0286 | 0.1 | 0.1 |